Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK5 | Q8IW41 | 3/20 | 0.42 |
| ▸ | SYK | P43405 | 3/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
| ▸ | STAT3 | P40763 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 3/20 | 0.37 |
| ▸ | MAPKAPK2 | P49137 | 7/20 | 0.37 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.37 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25822767 | 0.91 | SYK (0.38) | MAPKAPK5SYKJAK2FYN | |
| SCHEMBL25822732 | 0.90 | SYK (0.48) | SYKJAK2 | |
| SCHEMBL25822739 | 0.82 | MAPKAPK5 (0.49) | MAPKAPK5MAP4K4EGFRMAPKAPK2MAP4K1 | |
| SCHEMBL25822683 | 0.79 | MAPKAPK5 (0.54) | MAPKAPK5SYKMAP4K4JAK2JAK3 | |
| SCHEMBL25822689 | 0.76 | MAPKAPK5 (0.51) | MAPKAPK5SYKJAK2EGFRMAPKAPK2 | |
| SCHEMBL25822741 | 0.76 | SYK (0.51) | MAPKAPK5SYKJAK2EGFRFYN | |
| SCHEMBL25822735 | 0.75 | MAPKAPK5 (0.52) | MAPKAPK5EGFRMAPKAPK2FYN | |
| SCHEMBL25823381 | 0.73 | MAPKAPK5 (0.50) | MAPKAPK5EGFRMAPKAPK2FYN | |
| SCHEMBL25822740 | 0.72 | MAPKAPK5 (0.51) | MAPKAPK5EGFRMAPKAPK2 | |
| SCHEMBL25822675 | 0.72 | MAPKAPK5 (0.67) | MAPKAPK5SYKJAK2FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219960-A1 | 1H-PYRAZOLE DERIVATIVE AND APPLICATION THEREOF AS DUAL TARGET INHIBITOR OF SYK AND VEGFR2 | OCUMENSION THERAPEUTICS (SUZHOU) CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219960-A1 | 1H-PYRAZOLE DERIVATIVE AND APPLICATION THEREOF AS DUAL TARGET INHIBITOR OF SYK AND VEGFR2 | SYK, KDR, FLT1 | MAPKAPK5 216/4885SYK 1/4885MAP4K4 543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.